

Marijo Bilusic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2380867/publications.pdf>

Version: 2024-02-01

67
papers

2,273
citations

430874

18
h-index

289244

40
g-index

67
all docs

67
docs citations

67
times ranked

3965
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 735-740.	3.9	12
2	What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 561-563.	2.4	6
3	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	7.0	22
4	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 435-444.	2.5	7
5	Molecular Profiling of Exceptional Responders to Cancer Therapy. <i>Oncologist</i> , 2021, 26, 186-195.	3.7	15
6	Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 799-800.	6.3	10
7	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
8	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
9	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2617-2617.	1.6	0
10	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2501-2501.	1.6	14
11	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e17044-e17044.	1.6	1
12	A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2659-TPS2659.	1.6	0
13	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5096-TPS5096.	1.6	3
14	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6092-TPS6092.	1.6	2
15	Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. <i>Cancer Research Communications</i> , 2021, 1, 127-139.	1.7	8
16	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.	1.8	7
17	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 490.	3.5	14
18	<p>Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7321-7330.	1.9	24

#	ARTICLE	IF	CITATIONS
19	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
20	Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 603248.	2.8	2
21	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 99-109.	7.0	116
22	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
23	Cancer Vaccines. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 199-214.	2.2	84
24	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 352.e25-352.e30.	1.6	4
25	A Case of Anti-“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e549-e552.	1.9	5
26	Anti-PD-L1/TGF β 2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 93.e1-93.e11.	1.6	40
27	Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. , 2018, 6, 150.		27
28	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
29	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. <i>European Urology Oncology</i> , 2018, 1, 54-60.	5.4	26
30	Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5084-5084.	1.6	1
31	CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5096-TPS5096.	1.6	2
32	A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.. <i>Journal of Clinical Oncology</i> , 2018, 36, 163-163.	1.6	35
33	Immunotherapy for biochemically recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 215-215.	1.6	5
34	Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. <i>Current Oncology Reports</i> , 2017, 19, 27.	4.0	16
35	Editorial: Local Immunotherapy: A Way to Convert Tumors From “Cold” to “Hot”. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	15
36	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2561-2574.	3.3	91

#	ARTICLE	IF	CITATIONS
37	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6764-6770.	7.0	173
38	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e337-e343.	1.9	18
39	Avelumab in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5037-5037.	1.6	2
40	Molecular profiling of cancer outliers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13025-e13025.	1.6	2
41	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. <i>Oncotarget</i> , 2016, 7, 68206-68228.	1.8	8
42	Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e755-e764.	2.5	83
43	Nivolumab-associated acute glomerulonephritis: a case report and literature review. <i>BMC Nephrology</i> , 2016, 17, 188.	1.8	91
44	Castration Resistant Prostate Cancer: Role of Chemotherapy. , 2016, , 509-514.		0
45	Human capital costs of obtaining oral anticancer medications.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6506-6506.	1.6	2
46	Small cell carcinoma of the bladder: Comparison of survival in various treatment modalities at Fox Chase Cancer Center (FCCC) from 1995 to 2015.. <i>Journal of Clinical Oncology</i> , 2016, 34, 465-465.	1.6	1
47	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 142-149.	1.9	7
48	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 68, 959-967.	1.9	395
49	Targeted radionuclides for prostate cancer bone metastases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 2-6.	1.6	0
50	Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 320-320.	1.6	5
51	Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4514-4514.	1.6	0
52	Anti-angiogenesis in prostate cancer: knocked down but not out. <i>Asian Journal of Andrology</i> , 2014, 16, 372.	1.6	20
53	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 225-234.	4.2	86
54	Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy?. <i>Urology</i> , 2014, 84, 1152-1156.	1.0	12

#	ARTICLE	IF	CITATIONS
55	Spontaneous Tumor Lysis Syndrome in Renal Cell Carcinoma: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e225-e227.	1.9	15
56	Effect of Talactoferrin Alfa on the Immune System in Adults With Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 821-822.	3.7	9
57	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies. , 2013, , 455-474.		0
58	Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. <i>Cancers</i> , 2012, 4, 1229-1246.	3.7	3
59	Therapeutic Cancer Vaccines. <i>American Journal of Therapeutics</i> , 2012, 19, e172-e181.	0.9	24
60	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	2.2	75
61	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 109-117.	4.2	34
62	Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. <i>Vaccine</i> , 2011, 29, 6485-6497.	3.8	20
63	Early Adolescence and Suicidal Ideations in Croatia. <i>Crisis</i> , 2011, 32, 334-345.	1.2	15
64	Cabazitaxel: a new drug for metastatic prostate cancer. <i>Asian Journal of Andrology</i> , 2011, 13, 185-186.	1.6	2
65	Recurrent Bulbar Paralysis Caused by Botulinum Toxin Type B. <i>Clinical Infectious Diseases</i> , 2008, 46, e72-e74.	5.8	4
66	Genetically Hypertensive Brown Norway Congenic Rat Strains Suggest Intermediate Traits Underlying Genetic Hypertension. <i>Croatian Medical Journal</i> , 2008, 49, 586-599.	0.7	8
67	Mapping the Genetic Determinants of Hypertension, Metabolic Diseases, and Related Phenotypes in the Lyon Hypertensive Rat. <i>Hypertension</i> , 2004, 44, 695-701.	2.7	56